AbCellera Biologics Inc. (ABCL) Insider Trading Activity

NASDAQ$3.56
Market Cap
$1.07B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
134 of 827
Rank in Industry
85 of 469

ABCL Insider Trading Activity

ABCL Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$1,118,771
4
100
Sells
$0
0
0

Related Transactions

Thermopylae Holdings Ltd.10 percent owner
1
$742,243
0
$0
$742,243
Montalbano John S.director
3
$376,528
0
$0
$376,528

About AbCellera Biologics Inc.

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Insider Activity of AbCellera Biologics Inc.

Over the last 12 months, insiders at AbCellera Biologics Inc. have bought $1.12M and sold $0 worth of AbCellera Biologics Inc. stock.

On average, over the past 5 years, insiders at AbCellera Biologics Inc. have bought $30.26M and sold $394.03M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Thermopylae Holdings Ltd. (10 percent owner) — $742,243. Montalbano John S. (director) — $376,528.

The last purchase of 50,000 shares for transaction amount of $178,460 was made by Montalbano John S. (director) on 2025‑11‑26.

List of Insider Buy and Sell Transactions, AbCellera Biologics Inc.

2025-11-26PurchaseMontalbano John S.director
50,000
0.0164%
$3.57
$178,460
-2.67%
2025-03-11PurchaseThermopylae Holdings Ltd.10 percent owner
343,631
0.1117%
$2.16
$742,243
+70.40%
2025-03-10PurchaseMontalbano John S.director
25,000
0.0088%
$2.30
$57,500
+71.85%
2025-03-06PurchaseMontalbano John S.director
60,000
0.0198%
$2.34
$140,568
+57.91%
2024-08-29PurchaseThermopylae Holdings Ltd.10 percent owner
283,516
0.0993%
$2.61
$739,977
+10.08%
2023-11-08PurchaseMontalbano John S.director
10,000
0.0037%
$4.46
$44,600
-7.89%
2023-11-06PurchaseMontalbano John S.director
20,000
0.0071%
$4.64
$92,800
-13.76%
2023-09-22PurchaseHayden Michael Rdirector
20,000
0.0066%
$4.91
$98,200
-14.30%
2023-09-12PurchaseLecault VeroniqueChief Operating Officer
20,000
0.007%
$5.19
$103,800
-15.56%
2023-08-08PurchaseHayden Michael Rdirector
30,000
0.0104%
$5.90
$177,000
-23.77%
2023-05-26PurchaseThermopylae Holdings Ltd.10 percent owner
153,000
0.051%
$6.52
$997,728
-26.25%
2023-05-26PurchaseBooth AndrewChief Financial Officer
14,500
0.0051%
$6.85
$99,325
-26.25%
2022-12-16PurchaseThermopylae Holdings Ltd.director
85,102
0.0295%
$10.10
$859,249
-33.50%
2022-08-19PurchaseThermopylae Holdings Ltd.10 percent owner
200,000
0.0702%
$11.46
$2.29M
-20.94%
2022-06-14PurchaseThermopylae Holdings Ltd.10 percent owner
9,173
0.0029%
$8.05
$73,842
+16.48%
2022-06-13PurchaseThermopylae Holdings Ltd.10 percent owner
54,915
0.0189%
$8.03
$441,066
+25.00%
2022-06-06PurchaseThermopylae Holdings Ltd.10 percent owner
64,545
0.0222%
$7.50
$483,965
+33.64%
2022-05-16PurchaseLecault VeroniqueChief Operating Officer
200,000
0.057%
$6.34
$1.27M
+31.24%
2022-05-13PurchaseThermopylae Holdings Ltd.10 percent owner
300,000
0.1057%
$7.26
$2.18M
+41.77%
2022-05-12PurchaseThermopylae Holdings Ltd.10 percent owner
1.41M
0.4723%
$6.41
$9.02M
+52.76%
Total: 41
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
Thermopylae Holdings Ltd.10 percent owner
56143640
18.7571%
$199.87M111
+6.72%
Montalbano John S.director
221000
0.0738%
$786,760.0090
<0.0001%
THIEL PETERdirector
10179880
3.401%
$36.24M10
<0.0001%
Lecault VeroniqueChief Operating Officer
2040122
0.6816%
$7.26M41
<0.0001%
Hayden Michael Rdirector
1323397
0.4421%
$4.71M31
<0.0001%
Hansen Carl L. G.Chief Executive Officer
233500
0.078%
$831,260.0001
Booth AndrewChief Financial Officer
153000
0.0511%
$544,680.0031
<0.0001%
HAMER JOHNdirector
128862
0.0431%
$458,748.7202
Stimart TrynChief Legal Officer
250
0.0001%
$890.0011
<0.0001%
Falconer EsterChief Technology Officer
0
0%
$001
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$8,217,280
112
46.33%
$1.12B
$607,159,124
92
3.55%
$1.08B
$61,783,526
37
18.57%
$1.08B
AbCellera Biologics Inc.
(ABCL)
$150,196,329
28
-8.09%
$1.07B
$7,598,498
27
34.68%
$1.03B
$103,156,698
27
19.10%
$1.01B
$49,750,490
17
37.19%
$1.04B
$276,750,010
16
-7.95%
$1.13B
$2,788,839
12
6.73%
$1.16B
$18,336,420
12
24.03%
$1.06B
$49,967,154
11
62.08%
$1.18B
$11,541,901
10
8.07%
$1.04B
$5,794,001
10
23.26%
$1.02B
$1,580,951
9
-14.18%
$1.08B
$93,268,646
8
-37.22%
$1.15B
$160,798,946
8
-3.92%
$993.02M
$46,235,722
6
-31.77%
$1.01B
$19,420,853
5
4.35%
$1.07B
$33,624,000
2
-50.37%
$996.99M

ABCL Institutional Investors: Active Positions

Increased Positions76+50.67%15M+13.39%
Decreased Positions61-40.67%19M-17.09%
New Positions34New4MNew
Sold Out Positions22Sold Out14MSold Out
Total Postitions165+10%104M-3.7%

ABCL Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Baker Bros. Advisors Lp$102,671.009.21%27.53M00%2025-09-30
Capital World Investors$49,837.004.47%13.36M00%2025-09-30
Baillie Gifford & Co$38,878.003.49%10.42M+62,962+0.61%2025-09-30
Two Sigma Investments, Lp$19,303.001.73%5.18M+1M+25.89%2025-09-30
Two Sigma Advisers, Lp$17,904.001.61%4.8M+729,600+17.93%2025-09-30
Arrowmark Colorado Holdings Llc$15,312.001.37%4.11M00%2025-09-30
Blackrock, Inc.$13,584.001.22%3.64M-39,015-1.06%2025-09-30
Renaissance Technologies Llc$12,536.001.12%3.36M+53,300+1.61%2025-09-30
Morgan Stanley$10,415.000.93%2.79M+2M+180.07%2025-09-30
Tang Capital Management Llc$9,698.000.87%2.6M00%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.